Search NEL Online

Journal Article 2012; 33(7): 684-688 PubMed PMID: 23391876 Citation  Keywords:  Adult, Aged, Cardiovascular Diseases:epidemiology, Circadian Rhythm:physiology, Cohort Studies, Comorbidity, Disorders of Excessive Somnolence:epidemiology, Female, Humans, Male, Middle Aged, Polysomnography, REM Sleep Behavior Disorder:epidemiology, Rest.   

BACKGROUND: Obstructive sleep apnoea (OSA) is a condition leading to excessive daytime sleepiness. The aim of the study was a) to study course of daytime sleepiness in patients with OSA and b) to find the most important nocturnal polysomnography parameters influencing daytime sleepiness in OSA.

METHODS: The cohort consisted of forty-five patients (6 women, 39 men) diagnosed with OSA. All patients underwent polysomnography, Multiple Sleep Latency Test (MSLT) and rated subjectively their daytime tendency to sleep with the Epworth Sleepiness Scale.

RESULTS: Sleep latency was significantly longer at 15:00 and at 17:00 hours compared to previous tests. A significant negative correlation was found between the mean of the MSLT sleep latency and a number of awakenings, the apnoea/hypopnoea index and oxygen desaturation index values.

CONCLUSIONS: The study showed the sleep latency prolongation at 15:00 and 17:00 hours respectively and confirmed connection of excessive daytime sleepiness to fragmentation of nocturnal sleep and OSA severity....

Read abstract  Full text PDF

Journal Article 2012; 33(Suppl 2): 102-107 PubMed PMID: 23183520 Citation  Keywords:  Adult, Cardiovascular Diseases:epidemiology, Cross-Sectional Studies, Female, Follow-Up Studies, Humans, Logistic Models, Male, Middle Aged, Multivariate Analysis, Prevalence, Retrospective Studies, Risk Factors, Risk Reduction Behavior, Smoking Cessation.   

OBJECTIVES: Smoking cessation is an essential part of cardiovascular disease (CVD) prevention. At the Center for Tobacco-Dependent (CTD), clients are screened to identify and reduce cardiovascular (CV) risk factors. In our study we have focused on the role of the CTD in reducing global CV risk.

METHODS: 1,334 CTD patients aged 25-64 years (52.2% men, mean age 44±12 years, Fagerström Test for Cigarette Dependence 6±2) were included in a retrospective cross-sectional survey. Medical history, blood samples and physical examination were analysed. Blood pressure, weight and exhaled CO were measured at each visit (12-months-follow-up). Patients' CV risk was scored. CO-verified abstinence according to CV risk and prevalence of detected CV risk factors were examined.

RESULTS: Among patients who had attended at least their first visit and a visit after one year, 37.9% (506/1,334) had stopped smoking. Among patients with a SCORE of <5%, the success rate was 44.3% (254/574) and 41.2% for patients at high CV risk (105/255, p=0.41). There was a trend towards a lower success rate among patients with CVD, but this difference was not significant. The smoking cessation rate among low and high CV risk patients at the baseline visit was identical (46.2%, resp. 47.3%, p=0.81). 3.1% (42/1,334) of patients were referred to a specialist for hypertension. 62.5% (223/357), without a prior history, were found to have dyslipidemia.

CONCLUSIONS: High CV risk patients have the same chance to stop smoking as low risk patients....

Read abstract  Full text PDF

Clinical Trial 2012; 33(Suppl 2): 98-101 PubMed PMID: 23183519 Citation  Keywords:  Aged, Cardiovascular Diseases:drug therapy, Drug Therapy, Combination, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors:administration & dosage, Male, Middle Aged, Muscle Weakness:chemically induced, Musculoskeletal Pain:chemically induced, .   

OBJECTIVES: Statins significantly reduce CV morbidity and mortality. Unfortunately, one of the side effects of statins is myopathy, for which statins cannot be administered in sufficient doses or administered at all. The aim of this study was to demonstrate the effect of coenzyme Q10 in patients with statin myopathy.

DESIGN/SETTING: Twenty eight patients aged 60.6±10.7 years were monitored (18 women and 10 men) and treated with different types and doses of statin. Muscle weakness and pain was monitored using a scale of one to ten, on which patients expressed the degree of their inconvenience. Examination of muscle problems was performed prior to administration of CQ10 and after 3 and 6 months of dosing. Statistical analysis was performed using Friedman test, Annova and Students t-test.

RESULTS: Pain decreased on average by 53.8% (p<0.0001), muscle weakness by 44.4% (p<0.0001). The CQ10 levels were increased by more than 194% (from 0,903 μg/ml to 2.66 μg/ml; p<0.0001).

CONCLUSION: After a six-month administration of coenzyme Q10, muscle pain and sensitivity statistically significantly decreased....

Read abstract  Full text PDF

Clinical Trial 2012; 33(Suppl 2): 78-82 PubMed PMID: 23183515 Citation  Keywords:  Adipose Tissue:pathology, Adiposity, Adolescent, Adult, Aged, Anthropometry:methods, Body Mass Index, European Continental Ancestry Group:statistics & numerical data, Female, Humans, Middle Aged, Obesity:diagnosis, Reproducibility of Results, Risk Factors.   

OBJECTIVES: The body mass index (BMI) has been the most commonly applied clinical measure to characterise body composition in individuals. However, the BMI has been criticised as being an inaccurate measure of body fatness. Recently, a new index reflecting body composition, the Body Adiposity Index (BAI) was proposed. The BAI was calculated using the equation BAI=((hip circumference)/ ((height)1.5) - 18).

AIM: The aim of this study was to compare estimates of body fat content, i.e., body adiposity index (BAI), BMI, waist-hip ratio (WHR) and waist and hip circumferences, with respect to their ability to predict the percentage of body fat (PBF).

RESULTS: To select an optimal surrogate for adiposity, we examined the correlation between body adiposity percentage as measured by BIA and several variables, including BAI, BMI and WHR. Correlations ranged from a high of 0.78 for BMI, 0.67 for BAI and 0.66 for waist circumference to a low value of 0.39 for the WHR index. The correlation between PBF and BAI (R=0.67, R2=0.45, p<0.001) and the correlation between PBF and BMI (R=0.78, R2=0.60, p<0.001) were of similar magnitude.

CONCLUSION: Based on our results and those of other studies, we can say that the BAI index is not a universally valid index that could be used in the place of the BMI index in a Caucasian population; indeed, it would not accurately reflect body fat mass and thus could lead to an increased risk of obesity. Further, WHR index is not a suitable for an estimation of body fat....

Read abstract  Full text PDF

Clinical Trial 2012; 33(Suppl 2): 68-72 PubMed PMID: 23183513 Citation  Keywords:  Adult, Aged, Biomarkers:blood, Cardiomyopathy, Dilated:blood, Cell-Derived Microparticles:metabolism, Endothelium, Vascular:metabolism, Heart Failure:blood, Heart-Assist Devices:adverse effects, Hemodynamics:physiology, Humans, Male, Middle Aged, Myocardi.   

OBJECTIVES: Recent technological breakthroughs in the design of reliable systems for long term non-pulsatile mechanical heart support offer the possibility to study the effect of continuous blood flow in the vascular system. Generally, it is assumed that the absence of physiological pulsatile flow leads to prothrombogenic and proatherogenic changes. We investigated the change in the circulating endothelial microparticle concentration as a marker of endothelial damage in patients implanted with a continuous-flow left ventricle assist device (LVAD).

METHODS: Endothelial microparticles were measured in 8 males (mean age 54.1±11.5 years) with terminal heart failure before and 3 months after implantation of an LVAD. The group consisted of 3 patients with dilated cardiomyopathy, 3 patients with ischemic cardiomyopathy, 1 patient with both conditions and 1 patient with congenital valvular disease. The concentration of endothelial microparticles was determined by ELISA Zymutest MP activity test.

RESULTS: We did not observe a significant change in the concentration of circulating endothelial microparticles measured before and 3 months after implantation (p=0.669). High inter-individual variability in response to implantation was found. However, no association between a change in endothelial microparticle concentration and heart failure aetiology or a significant clinical complication attributed to LVAD implantation was observed.

CONCLUSION: Results from this preliminary pilot study do not indicate that LVADs contribute to short-term vascular damage as defined by an increase in circulating endothelial microparticles....

Read abstract  Full text PDF

Journal Article 2012; 33(Suppl 2): 55-59 PubMed PMID: 23183511 Citation  Keywords:  Adult, Aged, Aged, 80 and over, Cohort Studies, Coronary Artery Disease:blood, Dyslipidemias:blood, Female, Humans, Hypolipidemic Agents:therapeutic use, Lipoprotein(a):blood, Logistic Models, Male, Middle Aged, Risk Factors, Severity of Illness Index,.   

OBJECTIVES: Lipoprotein (a) [Lp(a)], together with other serum lipoproteins have an important role in the pathogenesis of coronary heart disease. The objective of the study was to assess the association between plasma levels of Lp(a) with the extent of angiographically defined coronary artery disease (CAD).

PATIENTS AND METHODS: A total of 518 consecutive patients (66 % males) underwent coronary angiography in connection with lipids and lipoprotein determinations between 1st January and 31st May 2010. Most of the patients were treated with lipid lowering therapy (77 % statins). Modified angiographic Gensini Score (GS) and adjusted angiographic score (AS) were used to reflect the extent of coronary atherosclerosis.

RESULTS: Both GS and AS angiographic scores correlated significantly with age, male gender, statin therapy and inversely with left ventricular ejection fraction (p<0.05-0.01 for all). The results showed significant inverse correlation of HDL cholesterol levels with GS and AS (r=-0.16, p<0.001), and apolipoprotein A levels with GS and AS (r=-0.20, p<0.0001) and a positive correlation of Lp(a) levels with angiographic score (r=0.13, p<0.01) and with adjusted angiographic score (r=0.16, p<0.01). Regression analysis showed only Lp(a) concentration was an independent lipid factor that correlated with the extent of CAD.

CONCLUSION: Only Lp(a) levels correlated with the extent of coronary artery disease as assessed with coronary angiography in patients treated with lipid lowering therapy....

Read abstract  Full text PDF

Journal Article 2012; 33(Suppl 2): 38-42 PubMed PMID: 23183508 Citation  Keywords:  Apolipoprotein A-I:blood, Apolipoproteins B:blood, Biomarkers:blood, Cardiovascular Diseases:blood, Cholesterol, HDL:blood, Cholesterol, LDL:blood, Female, Humans, Macrophages:metabolism, Middle Aged, Smoking:blood, Triglycerides:blood,.   

OBJECTIVES: It has been demonstrated that the deleterious effect of smoking on the cardiovascular system is mediated through a decrease in protective HDL cholesterol. In addition, women are more sensitive to the negative effects of smoking, although the exact mechanism underlying this phenomenon is currently unknown. In this study, we evaluated whether smoking habits could modify the association of HDL cholesterol and apolipoprotein A1 (ApoA1) with reverse cholesterol transport (RCT), as measured by cholesterol efflux (CHE), in middle-aged women.

DESIGN: The study group consisted of 39 healthy middle-aged women, 21 non-smokers (age 51.8±2.5 years, BMI 25.1±2.8 kg/m2) and 18 smokers (age 50.5±3.2 years, BMI 24.8±3.5 kg/m2). In addition to all traditional cardiovascular risk factors, CHE from macrophages, labelled during a 48-hour incubation in a medium containing [14C] cholesterol, to plasma acceptors in study subjects was established as a marker of reverse cholesterol transport.

RESULTS: CHE was significantly higher in non-smokers than in smokers (14.22±1.75% vs. 13.17±1.33%; p<0.05). Smoking habit had no effect on the association of HDL with ApoA1 or HDL with CHE. However, in contrast to the strong association of ApoA1 with CHE in non-smokers (r=0.62; p<0.01), no such strong association was found in smokers (r=0.38; n.s.). Main findings and conclusion: Based on our results, smoking can alter ApoA1-mediated reverse cholesterol transport in women....

Read abstract  Full text PDF

Journal Article 2012; 33(Suppl 2): 26-31 PubMed PMID: 23183506 Citation  Keywords:  Adult, Atherosclerosis:blood, Biomarkers:blood, Dyslipidemias:blood, Endothelium, Vascular:metabolism, Fatty Acid-Binding Proteins:blood, Female, Homeostasis:physiology, Humans, Intercellular Adhesion Molecule-1:blood, Linear Models, Male, Middle Aged, Mu.   

OBJECTIVES: Some findings support the role of serum adipocyte fatty acid-binding protein (A-FABP) as a key pro-inflammatory mediator that links obesity with cardiovascular diseases. The aim of the study was to evaluate the association of A-FABP with endothelial/hemostatic markers [von Willebrand factor (vWF), plasminogen activator inhibitor-1 (PAI-1), tissue-plasminogen activator (t-PA), soluble intercellular cell adhesion molecule-1 (s-ICAM-1) and soluble vascular cell adhesion molecule-1 (s-VCAM-1)] in asymptomatic dyslipidemic subjects.

DESIGN: We examined 105 dyslipidemic patients (with apolipoprotein B concentration ≥1.2 g/l and/or triglyceride (TG) concentration ≥1.5 mmol/l) without clinical manifestation of atherosclerosis and 50 normolipidemic healthy subjects, who served as a control group. Except of endothelial/hemostatic markers, anthropometric and lipid parameters, markers of insulin resistance and inflammation were assessed.

RESULTS: In dyslipidemic patients, A-FABP positively correlated with age (p<0.05), TG (p<0.05), insulin (p<0.05), homeostatic model assessment (HOMA) index (p<0.05), body mass index (p<0.001), waist circumference (p<0.05), high sensitivity C reactive protein (p<0.01), and vWF (p<0.05) and negatively with male gender (p<0.05). There were no correlations between A-FABP and PAI-1, t-PA, s-VCAM-1 or s-ICAM-1. By using linear multivariate regression analysis the positive association between A-FABP and vWF was independent of age, gender, insulin resistance, and visceral obesity.

CONCLUSION: Study displayed an independent positive association of A-FABP with vWF in clinically asymptomatic dyslipidemic subjects. Contribution of A-FABP in the process of endothelial dysfunction could help to explain the role of obesity in cardiovascular damage....

Read abstract  Full text PDF